Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Market Chatter: Eli Lilly Employees Accuse Factory Executive of Altering Regulatory Documents

05/05/2021 | 08:50am EDT


ę MT Newswires 2021
All news about ELI LILLY AND COMPANY
09:06aELI LILLY ANDá : JPMorgan Adjusts Price Target on Eli Lilly to $260 From $240, M..
MT
07:59aELI LILLY ANDá : to Compare Migraine Drugs Emgality, Nurtec ODT in Phase 4 Study
MT
06/14ELI LILLY ANDá : Significant Insider Selling Continues at Eli Lilly (LLY)
MT
06/14ELI LILLY ANDá : Lilly to Participate in Guggenheim Biopharma Strategy Series
PR
06/14ELI LILLY ANDá : Bernstein Adjusts Price Target on Eli Lilly to $250 From $205, ..
MT
06/14ELI LILLY ANDá : Goldman Sachs Adjusts Eli Lilly's Price Target to $270 From $25..
MT
06/14Fiserv Appoints Wafaa Mamilli to Board of Directors
AQ
06/11ELI LILLY ANDá : Significant Insider Selling in Shares of Eli Lilly (LLY) Contin..
MT
06/11INSIDER TRENDS : Insider Sales Continue 90-Day Trend at Eli Lilly
MT
06/11ELI LILLY ANDá : Thinking about trading options or stock in Crispr Therapeutics,..
PR
More news
Financials (USD)
Sales 2021 27 273 M - -
Net income 2021 6 537 M - -
Net Debt 2021 11 213 M - -
P/E ratio 2021 31,1x
Yield 2021 1,47%
Capitalization 206 B 206 B -
EV / Sales 2021 7,95x
EV / Sales 2022 7,73x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 222,09 $
Last Close Price 226,10 $
Spread / Highest target 19,4%
Spread / Average Target -1,77%
Spread / Lowest Target -22,6%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY33.91%205 531
JOHNSON & JOHNSON5.08%435 485
ROCHE HOLDING AG10.58%328 513
PFIZER, INC.7.66%221 837
NOVARTIS AG0.23%209 350
ABBVIE INC.7.70%203 822